国际多中心评估5型长QT综合征:一种低外显率的原发性心律失常疾病
该研究通过国际多中心协作,纳入推定常染色体显性LQT5患者229例和隐性2型Jervell and Lange-Nielsen综合征患者19例,评估KCNE1变异的心电图外显率和基因型-表型分离。结果显示,杂合基因阳性家属的心电图外显率仅20.7%,先证者明确心律失常事件发生率为16.9%,而家属为1.4%(调整HR 11.6,95%CI 2.6-52.2,P=0.001)。结论提示推定/确认的KCNE1功能缺失变异易致QT延长,但低外显率表明多数个体临床不表现。
要点
- LQT5先证者QTc较基因阳性家属更长,且心律失常事件风险显著增高。
- 杂合基因阳性家属心电图外显率低(20.7%),多数不表现临床表型。
- 2型Jervell and Lange-Nielsen综合征患者事件发生率与杂合队列无显著差异。
核心结论
- 推定/确认的KCNE1功能缺失变异易致QT延长,但低心电图外显率提示多数个体临床不表现。
研究设计与样本
- 国际多中心研究,纳入22个遗传心律失常门诊和4个登记处、9个国家的推定LQT5患者229例和2型Jervell and Lange-Nielsen综合征患者19例。
主要发现
- 推定LQT5先证者平均QTc为476.9±38.6 ms,基因阳性家属为441.8±30.9 ms(P<0.001)。
- 杂合基因阳性家属心电图外显率为20.7%(29/140)。
- 先证者明确心律失常事件发生率为16.9%(15/89),家属为1.4%(2/140),调整HR 11.6(95%CI 2.6-52.2),P=0.001。
- 2型Jervell and Lange-Nielsen综合征患者事件发生率为10.5%(2/19),与杂合队列相比HR 1.7(95%CI 0.3-10.8),P=0.590。
- 32个KCNE1变异在gnomAD中的累积频率为0.238%,比预期所有LQT5总患病率0.001%高238倍。
关键数值与推荐
- 心电图外显率定义为就诊心电图QTc>460 ms。
- 复合主要终点包括适当ICD放电、复苏的心脏骤停和心源性猝死。
临床怎么用
- 对携带KCNE1变异者应评估QTc,但需注意多数杂合家属外显率低,临床表型轻微。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Insight into type 5 long QT syndrome (LQT5) has been limited to case reports and small family series. Improved understanding of the clinical phenotype and genetic features associated with rare KCNE1 variants implicated in LQT5 was sought through an international multicenter collaboration. METHODS: Patients with either presumed autosomal dominant LQT5 (N = 229) or the recessive Type 2 Jervell and Lange-Nielsen syndrome (N = 19) were enrolled from 22 genetic arrhythmia clinics and 4 registries from 9 countries. KCNE1 variants were evaluated for ECG penetrance (defined as QTc >460 ms on presenting ECG) and genotype-phenotype segregation. Multivariable Cox regression was used to compare the associations between clinical and genetic variables with a composite primary outcome of definite arrhythmic events, including appropriate implantable cardioverter-defibrillator shocks, aborted cardiac arrest, and sudden cardiac death. RESULTS: A total of 32 distinct KCNE1 rare variants were identified in 89 probands and 140 genotype positive family members with presumed LQT5 and an additional 19 Type 2 Jervell and Lange-Nielsen syndrome patients. Among presumed LQT5 patients, the mean QTc on presenting ECG was significantly longer in probands (476.9±38.6 ms) compared with genotype positive family members (441.8±30.9 ms, P<0.001). ECG penetrance for heterozygous genotype positive family members was 20.7% (29/140). A definite arrhythmic event was experienced in 16.9% (15/89) of heterozygous probands in comparison with 1.4% (2/140) of family members (adjusted hazard ratio [HR] 11.6 [95% CI, 2.6-52.2]; P=0.001). Event incidence did not differ significantly for Type 2 Jervell and Lange-Nielsen syndrome patients relative to the overall heterozygous cohort (10.5% [2/19]; HR 1.7 [95% CI, 0.3-10.8], P=0.590). The cumulative prevalence of the 32 KCNE1 variants in the Genome Aggregation Database, which is a human database of exome and genome sequencing data from now over 140 000 individuals, was 238-fold greater than the anticipated prevalence of all LQT5 combined (0.238% vs 0.001%). CONCLUSIONS: The present study suggests that putative/confirmed loss-of-function KCNE1 variants predispose to QT prolongation, however, the low ECG penetrance observed suggests they do not manifest clinically in the majority of individuals, aligning with the mild phenotype observed for Type 2 Jervell and Lange-Nielsen syndrome patients.
引用
- Roberts JD, Asaki SY, Mazzanti A, et al. An International Multicenter Evaluation of Type 5 Long QT Syndrome: A Low Penetrant Primary Arrhythmic Condition. Circulation. 2020. PMID: 31941373. doi:10.1161/CIRCULATIONAHA.119.043114
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。